Roche's Actemra receives FDA breakthrough therapy designation
Wednesday, June 10, 2015
Roche said it received breakthrough therapy designation from the U.S. health regulator for its Actemra treatment in systemic sclerosis.
The Basel-based drugmaker said it will present new data from two studies on the drug in patients with early rheumatoid arthritis and systemic juvenile idiopathic arthritis at a rheumatism conference in Rome this week.
in.reuters.com
